| abstract |
The present invention relates to a composition for the prevention or treatment of tau-related diseases, in particular, it is characterized in that it contains levosimendan and rivastigmine together, so that it is better than when levosimendan is used alone. The tau aggregation inhibitory effect is remarkably excellent, the tau aggregation inhibitory effect is superior to the combination of other compounds, and there is no cytotoxicity, so it can be effectively used for the prevention and/or treatment of tau-related diseases, including neurodegenerative diseases. |